Trial Profile

Phase 1/2a, Proof-of-Concept, Multicenter, Parallel, Vehicle-Controlled, Double-Masked, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of IVW-1001 Ophthalmic Eyelid Wipe in Subjects With Dry Eye Disease

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 18 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 May 2026 Results presented in the IVIEW Therapeutics Media Release.
15 May 2026 According to an IVIEW Therapeutics media release, the data from the trial were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, held May 3-7, 2026, in Denver, Colorado.
15 Jan 2026 According to an IVIEW Therapeutics media release, the data from the trial will be presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, to be held in Denver, Colorado on May 3-7, 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com